Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy

Alectinib has been approved as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinoma. Oncologists are also exploring the possibility of applying alectinib in the perioperative period. Here, we present a patient with locally advanced lung adenocarcinoma asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Peijun, Zhao, Qingchun, Li, Yongwen, Shi, Ruifeng, Zhu, Guangsheng, Zhang, Zihe, Zhang, Hongbing, Liu, Minghui, Wei, Sen, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470069/
https://www.ncbi.nlm.nih.gov/pubmed/37663243
http://dx.doi.org/10.3389/fphar.2023.1140894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470069/
https://www.ncbi.nlm.nih.gov/pubmed/37663243
http://dx.doi.org/10.3389/fphar.2023.1140894

Ejemplares similares